2005

Indianapolis, Ind. - Guidant Corporation (NYSE: GDT), a world leader in the treatment of cardiac and vascular disease, today responded to statements by Johnson & Johnson on its pending acquisition...

MULTI-LINK VISION® RX Coronary Stent System Provides Thin Struts, Superb Deliverability and Excellent Clinical Results Indianapolis, Ind. and Tokyo - Guidant Corporation (NYSE: GDT) today...

High Energy System Addresses Growing Physician Demand for More Defibrillation Energy Indianapolis, IN and St. Paul, MN - Guidant Corporation (NYSE: GDT) today announced U.S. Food and Drug...

Indianapolis, Ind. - Guidant Corporation (NYSE: GDT) said today that it is informing physicians about two separate failure modes, each occurring at a low rate, being monitored within the...

Indianapolis, Ind. - Guidant announced today that the U.S. Food and Drug Administration (FDA) has completed its inspection of Guidant's Cardiac Rhythm Management facilities in St. Paul, Minnesota,...

Successful Inspection Brings Company One Step Closer to European Approval; Drug Eluting Stent Milestone Results in Payment to Novartis in Third Quarter Indianapolis, Ind. - Guidant Corporation...

Innovative Technology Directed Toward Compliance in Heart Failure Patients at Risk of Sudden Cardiac Death Indianapolis, Ind. and St. Paul, Minn. - Guidant Corporation (NYSE: GDT) today announced...

European Commission Ruling Necessitates Organizational and Staffing Adjustments Indianapolis, Ind. - Guidant Corporation (NYSE: GDT) today announced that as a result of the European Commission...

Approval Sufficient for Completion of Pivotal Trial Indianapolis, Ind. - Guidant Corporation (NYSE: GDT) today announced that the company has received approval from the U.S. Food and Drug...